Pacira BioSciences, Inc. (PCRX) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Total Assets Chart for Pacira BioSciences, Inc.
Pacira BioSciences, Inc. (PCRX) total assets for FY2025 were USD 1.3B, a -18.6% change from FY2024. Pacira BioSciences, Inc.'s total assets grew from USD 50.5M in 2008 to USD 1.3B in 2025 (2402.8% over 17 years). Total assets compound annual growth rate: 5-year CAGR of -0.2%, 10-year CAGR of 12.5%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $1.45B
- Implied Share Price
- $36.34
- Enterprise Value
- $1.14B
- Revenue (TTM)
- $746.16M
- EBITDA
- $123.97M
- Profit Margin
- 1.96%
- Trailing P/E
- 103.83
- Forward P/E
- 6.25
- Price/Book (MRQ)
- 1.46
- Price/Sales (TTM)
- 1.94
- EV/EBITDA
- 9.84
- EV/Revenue
- 1.53
- Dividend Yield
- —
- Book Value
- $16.87
- Free Cash Flow (FY2025)
- $136.66M
- Free Cash Flow Yield
- 9.42%
Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.